Global Health Ltd. Results

Q2FY25 Quarterly Result Announced for Global Health Ltd.

Healthcare Facilities company Global Health announced Q2FY25 results Financial Highlights: Total income of Rs 9,748 million, growth of 12.7% YoY and 10.4% QoQ. EBITDA was Rs 2,465 million, growth of 5.5% YoY and 18.4% QoQ. EBITDA margins were at 25.3% in Q2FY25. Profit after tax was Rs 1,308 million, growth of 4.5% YoY and 23.1% QoQ. PAT margins were 13.4% compared to 14.5% in Q2FY24. Net cash surplus of Rs 7,186 million at the end of 30th September, 2024. During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds in Q2FY25. Average occupied bed days increased by 9.1% YoY, with strong occupancy of 64.3% on increased bed capacity. In-patients count increased by 8.8% YoY; Out-patients count increased by 6.6% YoY. ARPOB marginally grew by 1.9% YoY to Rs 62,140 in Q2FY25 due to combination of tariff increase in Matured facility and change in case mix across the group. Matured hospitals revenue was Rs 6,882 million, strong growth of 13.5% YoY and 7.8% on QoQ basis. EBITDA was Rs 1,739 million, growth of 12.5% YoY and 9.4% on QoQ basis. Developing hospitals revenue was Rs 2,754 million, growth of 4.2% YoY and 16.2% on QoQ basis. EBITDA was Rs 823 million, down by 8.2% YoY and strong growth of 41.7% on QoQ basis. During the quarter, International Patients Revenue was Rs 513 million. Out-patient pharmacy (Hospital + Retail) continues to register strong growth. Revenue increased by 24.5% from Rs 298 million in Q2FY24 to Rs 371 million in Q2FY25. Other Highlights: During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds. 25 doctors on-boarded across facilities to further strengthen clinical capability. New Da Vinci Xi robot introduced in Lucknow and additional Da Vinci Xi robot operationalized in Gurugram. Medanta Gurugram performed its first CAR-T Cell therapy, an advanced cancer treatment that harnesses the power of the patient’s own immune system to fight cancer. Medanta Gurugram achieves significant milestone of completing 3,000 kidney transplants. Medanta Lucknow completes 100 breast cancer surgeries. Medanta Gurugram doctors successfully performed bilateral lung transplant in a patient with ILD and complex autoimmune condition. Medanta Gurugram doctors uses minimally invasive unique approach to treat rare heart condition idiopathic chylopericardium. Complex and severe genetic disorder Wiskott Aldrich Syndrome cured at Medanta Gurugram using half-match stem cell transplant. Pankaj Sahni, Group CEO and Director, said: “We are pleased to report a strong performance this quarter, achieving our highest-ever quarterly Revenue and EBITDA. Growth momentum was robust across our network hospitals, as we continue to invest in cutting-edge technologies, enhance clinical capabilities through the on-boarding of senior clinicians, and expand our network by adding more beds. I am also excited to announce that Medanta has recently signed an Operations and Management agreement to operate and manage a state-of-the-art, 750-bed super-specialty hospital in Pitampura, New Delhi. The hospital will be jointly built by Medanta and our partners Dr. Narayan Dutt Shirmali Foundation International Charitable Trust Society. This expansion reinforces our vision of creating a high-quality healthcare delivery platform, strengthens our presence in Delhi/NCR, and underscores our commitment to elevating patient care in the region through world-class services and infrastructure.”

Q4FY24 Quarterly & FY24 Annual Result Announced for Global Health Ltd.

Healthcare Facilities company Global Health announced consolidated Q4FY24 & FY24 results: FY24 Financial Highlights: Total income of Rs 33,498 million, growth of 21% YoY EBITDA of Rs 8,737 million compared to Rs 6,771 million, growth of 29% YoY EBITDA margins improved by 154 bps to 26.1% Profit after tax of Rs 4,781 million, growth of 47% YoY Net cash surplus of Rs 7,720 million Average occupied bed days increased by 14% YoY, representing an occupancy of 62% on increased bed capacity In-patients count increased by 15%; Out-patient count increased by 18% in FY24 ARPOB grew by 4.7% to Rs 61,890 Developing hospitals revenue share of consolidated revenue increased from 27% in FY23 to 30% in FY24 amounting to Rs 9,948 million. Developing hospital EBITDA share of consolidated EBITDA increased from 32% in FY23 to 37% in FY24 amounting to Rs 3,208 million During the period, International Patients Revenue increased by 24% to Rs 1,935 million, driven by increased volume in international patient admissions and higher realizations In house OPD Pharmacy business continues to register strong growth. Revenue increased by 32% from Rs 850 million in FY23 to Rs 1,121 million in FY24 Q4FY24 Financial Highlights: Total income of Rs 8,361 million; growth of 14% YoY EBITDA of Rs 2,068 million; growth of 8% YoY EBITDA margins remained stable at 24.7% Profit after tax of Rs 1,273 million; growth of 26% YoY Average occupied bed days increased by 9% YoY, representing an occupancy of 59% on increased bed capacity ARPOB grew by 4% to Rs 63,063; In-patient count increased by 10% YoY; Out-patient count increased by 11% YoY Commenting on FY2024 results, Pankaj Sahni, Group CEO and Director said: “I am pleased to inform that keeping with our consistent focus on quality care, Medanta has been recognized by Newsweek as India's 'Best Private Hospital' for the fifth consecutive year. Medanta Gurugram is also the only Indian private hospital to feature in the top 200 hospitals in the world. The continued focus on providing our patients with the highest quality of care has enabled Medanta to deliver strong financial results during the year. We remain dedicated to executing our core strategy and delivering on our upcoming projects. Medanta is well-positioned to drive near-term growth with calibrated bed capacity expansions at existing hospitals and new facilities.”

Q3FY24 Quarterly Result Announced for Global Health Ltd.

Healthcare Facilities company Global Health announced Q3FY24 results: Financial Performance: Total Income: The consolidated total income for Global Health increased by 21% YoY to Rs 8,545 million in Q3FY24. EBITDA: The company's EBITDA saw a substantial rise of 36% YoY, reaching Rs 2,340 million, with EBITDA margins expanding significantly by 305 basis points to 27.4%. Net Profit: Net profit experienced remarkable growth, up by 53% YoY to Rs 1,235 million, while the PAT margins improved from 11.4% to 14.5%. Operational Highlights: Bed Occupancy: The average occupied bed days increased by 15% YoY, which corresponds to an average occupancy rate of 64% for the quarter. Patient Volume: The company reported a 13% YoY increase in in-patient count and a 20% YoY increase in out-patient count. Average Revenue Per Occupied Bed (ARPOB): ARPOB saw a growth of 4% YoY, reaching Rs 60,571, primarily driven by higher realizations at the Gurugram unit. Business Growth: Developing Hospitals Performance: Developing hospitals witnessed revenue growth of 33%, contributing Rs 2,742 million, which amounted to 32% of the total revenue share. Their EBITDA contribution increased from 37% to 41%, summing up to Rs 968 million. Matured Hospitals Performance: The matured hospitals also demonstrated strong performance, with a revenue increase of 17% and EBITDA growth of 37%, totaling Rs 5,875 million and Rs 1,484 million respectively. International Patients Revenue: Revenue from international patients rose by 6% YoY to Rs 473 million, owing to increased volume and realization. OPD Pharmacy Business: There was a 28% YoY increase in revenue from the OPD pharmacy business, up from Rs 224 million in Q3 FY23 to Rs 287 million in Q3 FY24. Strategic Developments: Doctor Onboarding: Medanta onboarded a total of 253 doctors across their facilities during the first nine months of FY24, with 159 in matured hospitals and 94 in developing hospitals. Upcoming Hospital in Noida: Progress on the Medanta Noida hospital is well on track with the superstructure 82% complete and operations expected to start by the end of FY2025. New Joint Venture: Medanta and DLF formed a special-purpose vehicle company, GHL Hospital Limited, to construct and operate a super-specialty hospital in South Delhi. Pankaj Sahni, Group CEO, and Director, said: "I am pleased to report that Medanta has delivered strong year-on-year performance during the quarter ended December 31, 2023. In Q3FY24, both our matured and developing units delivered robust revenue growth of 17% and 33% YoY respectively. This growth was primarily driven by increased in-patient volume and improved realization. Our commitment remains unwavering in building a sustainable long-term business model and providing the highest quality care across our key markets."

Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Global Health Ltd.

Healthcare Facilities company Global Health announced Q2FY24 & H1FY24 results: Q2FY24: Total income of Rs 8,647 million; growth of 24.5% YoY EBITDA of Rs 2,336 million; growth of 35.7% YoY EBITDA margins improved from 24.8% in Q2FY23 to 27% in Q2FY24 Profit after tax was at Rs 1,252 million; up by 46.1% YoY Average Occupied bed days increased by 17.8% YoY, representing an occupancy of 64.9% in Q2FY24 ARPOB grew by 4.8% YoY to Rs 61,003; In-patient count increased by 19.4% and Out-patient count increased by 23.2% YoY Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 27% in Q2FY23 to 31% in Q2FY24 amounting to Rs 2,643 million. Developing Hospital EBITDA share increased from 33% in Q2FY23 to 38% in Q2FY24 amounting to Rs 897 million Matured hospitals registered a strong growth of 19.5% YoY and EBITDA growth of 32.8% YoY amounting to Rs 6,064 million and Rs 1,545 million respectively Revenue from international patients increased by 20% YoY to Rs 507 million driven by increased volumes and realization OPD pharmacy business continues to register strong growth. Revenue increased by 39% YoY from Rs 215 million in Q2FY23 to Rs 298 million in Q2FY24 H1FY24: Total income of Rs 16,592 million; growth of 25.6% YoY EBITDA of Rs 4,329 million; growth of 38.0% YoY EBITDA margins improved from 23.7 % in H1FY23 to 26.1% in H1FY24 Profit after tax of Rs 2,272 million; growth of 57.3% YoY Average Occupied bed days increased by 17.1% YoY, representing an occupancy of 61.5% in H1FY24 ARPOB grew by 5.9% YoY to Rs 62,011 in H1FY24; In-patient volume increased by 19.4% and Out-patient volume increased by 20.5% YoY in H1FY24 incurred Capex of Rs 1,276 million incurred during H1FY24, out of which Rs 308 million was incurred towards Noida hospital Commenting on Q2FY24 results, Pankaj Sahni, Group CEO and Director said, “We are pleased to report that the Company continues to deliver strong year-on-year and sequential growth across key performance indicators. The growth was seen at both matured and developing units, driven by higher patient volumes, underpinned by bed growth, doctor additions, and technology advancement. During the quarter, we received NABH accreditation for Patna Hospital, this accreditation reflects our commitment to deliver the highest quality healthcare in underserved markets. Our Noida hospital construction is on track and is expected to commence operations by FY2025 the end. As we move forward, we remain committed to executing our planned strategies while maintaining the highest quality and ethics as demonstrated by our ‘Medanta Model of Care’.